AMTI - Applied Molecular posts additional data from early-stage AMT-101 ulcerative colitis trial

Applied Molecular Transport (AMTI) announces additional Phase 1b data for oral AMT-101 in ulcerative colitis ((UC)) patients.The Phase 1b multiple ascending dose trial evaluated safety and was a randomized, placebo-controlled 3:1, double-blind trial that included 16 patients with active UC.Key findings from the study support oral AMT-101 actively exerts immunomodulatory effect resulting in local and systemic benefit, the company said.Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology, Applied Molecular added.Applied Molecular's chief medical officer Bittoo Kanwar called the study results "compelling", and said that the company has designed four global trials to generate data in monotherapy and combination regimens in both biologic-naïve and -experienced patient settings.The company said that it expects to report topline data readouts for the four Phase 2 studies beginning in the second half of this year.

For further details see:

Applied Molecular posts additional data from early-stage AMT-101 ulcerative colitis trial